Atomo Diagnostics: first-quarter revenue up 140%, but margins under pressure
Atomo Diagnostics reported first-quarter revenue up 140% to AUD 1.63 million, while gross margin fell to 26% and the EBITDA loss widened.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Atomo Diagnostics posted first-quarter revenue up 140% year on year, reaching AUD 1.63 million. The growth came mainly from HIV testing sales and OEM business.
At the same time, gross margin dropped to 26% and the EBITDA loss grew. According to TradingView, the company is targeting broader revenue through pipeline additions and manufacturing initiatives aimed at improving margins.
why it matters
For investors in small healthcare companies, two factors stand out: revenue growth alongside shrinking margins and a larger loss. Without timelines or specific figures for the new products, it is hard to judge when profitability might recover.
tags
instruments
sources
- Atomo Diagnostics: Revenue surged 140%, while pipeline expansion and margin improvement remain priorities — TradingView, 3 November 2026 at 03:54 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗